Exelixis | EXEL - Selling And Administration Expenses


Exelixis reported $154.56M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Exelixis USD 154.56M 6.93M Sep/2026
Genmab DKK 205M 39M Jun/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Merck USD 2.86B 25M Sep/2026
Moderna USD 282M 66M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sanofi EUR 2.63B 140M Jun/2026
Takeda JPY 271.71B 14.8B Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026